You are here

SARC016

Active
Phase 2 study of everolimus in combination with bevacizumab in patients with sporadic and neurofibromatosis type 1 related refractory malignant peripheral nerve sheath tumors
Type of Sarcoma: 
malignant peripheral nerve sheath tumor (MPNST) either sporadic or NF1 associated
Drug: 
bevacizumab and everolimus
Accrual Status: 
Open, Not Accruing
Overall Study Principal Investigator: 

Brigitte Widemann, MD
Senior Investigator, Pediatric Oncology Branch
National Cancer Institute

For more information about this trial and open sites: